Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
872 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,392 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (364)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07768358 | Tucatinib Continuation Study | not yet recruiting | Phase 4 | 175 | PfizerINDUSTRY | 0 | Aug 28, 2026 | clinicaltrials |
| NCT05753618 | Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy(REaCT-OGF) | recruiting | Phase 4 | 242 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 8, 2026 |
| NCT03664687 | Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)(REaCT-ZOL) | completed | Phase 4 | 211 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05376878 | An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis | recruiting | Phase 4 | 10 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05183828 | Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer | terminated | Phase 4 | 62 | University of WashingtonOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07589699 | Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP | not yet recruiting | Phase 4 | 59 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 15, 2026 | clinicaltrials |
| NCT07042581 | A Study of Revaree Plus in People With Breast Cancer | recruiting | Phase 4 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06920810 | Viscum Album for TNBC on Adjuvant Pembrolizumab(TNBNOBA) | recruiting | Phase 4 | 40 | Ilsan Cha hospitalOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04781959 | A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy | completed | Phase 4 | 233 | Ottawa Hospital Research InstituteOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06868017 | Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles | not yet recruiting | Phase 4 | 208 | The First Hospital of Jilin UniversityOTHER | 0 | Mar 10, 2025 | clinicaltrials |
| NCT04790305 | Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer | recruiting | Phase 4 | 1,072 | Fudan UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06217185 | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | recruiting | Phase 4 | 100 | Hebei Medical University Fourth HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05949424 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults(OPTI-DOSE) | unknown | Phase 4 | 30 | University Medical Center GroningenOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05843292 | Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer(NeoSTEP) | not yet recruiting | Phase 4 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT05036005 | Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)(NeoON) | unknown | Phase 4 | 108 | Institut fuer FrauengesundheitOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04248179 | The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery. | completed | Phase 4 | 36 | Zealand University HospitalOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT03948568 | Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)(REaCT-RETT) | completed | Phase 4 | 262 | Ottawa Hospital Research InstituteOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT03397914 | Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections | completed | Phase 4 | 70 | National Cancer Institute, EgyptOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT02816112 | Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia(REaCT-TC2) | completed | Phase 4 | 458 | Ottawa Hospital Research InstituteOTHER | 1 | May 27, 2020 | clinicaltrials |
| NCT02005770 | Anesthesia and Circulating Tumor Cells in Breast Cancer | completed | Phase 4 | 221 | University of ZurichOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT03348696 | Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients(REaCT-TAPS) | completed | Phase 4 | 124 | Ottawa Hospital Research InstituteOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT02816164 | A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia(REaCT-G2) | completed | Phase 4 | 324 | Ottawa Hospital Research InstituteOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT03799679 | Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer | unknown | Phase 4 | 60 | Fudan UniversityOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT03238703 | Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer | withdrawn | Phase 4 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 27, 2018 | clinicaltrials |
| NCT02982148 | Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients | unknown | Phase 4 | 352 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 5, 2016 | clinicaltrials |
| NCT00742222 | Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer(EXIBT) | completed | Phase 4 | 63 | Xoft, Inc.INDUSTRY | 1 | May 17, 2016 | clinicaltrials |
| NCT02615457 | Huaier Granule in Treating Women With Triple Negative Breast Cancer | unknown | Phase 4 | 300 | Shandong UniversityOTHER | 1 | Nov 26, 2015 | clinicaltrials |
| NCT01597999 | Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer | unknown | Phase 4 | 60 | Mahidol UniversityOTHER | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00616135 | Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy(RESTORE-2) | completed | Phase 4 | 71 | Cytori TherapeuticsINDUSTRY | 4 | May 17, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Aug 28, 2026source: clinicaltrials